Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | DRD3 | P35462 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5041464 | 0.79 | CHRNB2 (0.55) | HSD11B1CHRM2CHRM4CHRM5OPRM1 | |
| SCHEMBL2955795 | 0.73 | FUCA1 (0.60) | FUCA1CHRM2CHRM4CHRM5SIGMAR1 | |
| SCHEMBL10480299 | 0.72 | HSD11B1 (0.49) | HSD11B1FUCA1CHRM2CHRM4CHRM5 | |
| SCHEMBL20488466 | 0.70 | FUCA1 (0.60) | FUCA1CHRM2CHRM4CHRM5SIGMAR1 | |
| SCHEMBL6201186 | 0.69 | HRH3 (0.43) | HSD11B1FUCA1 | |
| SCHEMBL4318880 | 0.69 | HSD11B1 (0.65) | HSD11B1FUCA1CHRM2CHRM4CHRM5 | |
| Hydrochloric Acid SCHEMBL20488123 | 0.69 | FUCA1 (0.58) | FUCA1CHRM2CHRM4CHRM5SIGMAR1 | |
| SCHEMBL5750271 | 0.67 | FUCA1 (0.56) | FUCA1CHRM2CHRM4CHRM5SIGMAR1 | |
| SCHEMBL21793953 | 0.67 | FUCA1 (0.56) | FUCA1CHRM2CHRM4CHRM5SIGMAR1 | |
| SCHEMBL21793950 | 0.67 | FUCA1 (0.56) | FUCA1CHRM2CHRM4CHRM5SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3068774-B1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS INC (US) | 2019-12-25 | — | — | EP | disclosed |
| US-10364228-B2 | Azepane derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2019-07-30 | — | — | US | disclosed |
| US-20180044300-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2018-02-15 | — | — | US | disclosed |
| US-20180044300-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2018-02-15 | — | — | US | disclosed |
| US-9758489-B2 | Azepane derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9758489-B2 | Azepane derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-20150315159-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2015-11-05 | — | — | US | disclosed |
| US-20150315159-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2015-11-05 | — | — | US | disclosed |
| US-9115113-B2 | Azepane derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9115113-B2 | Azepane derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20150132258-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC., | 2015-05-14 | — | — | US | disclosed |
| US-20150132258-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC., | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315159-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HDGF, AZI2 | HSD11B1 89/4885FUCA1 3931/4885CHRM2 4416/4885 |
| US-10364228-B2 | Azepane derivatives and methods of treating hepatitis B infections | HAVCR2, HDGF, AZI2 | HSD11B1 89/4885FUCA1 3931/4885CHRM2 4416/4885 |
| US-20180044300-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HDGF, AZI2 | HSD11B1 89/4885FUCA1 3931/4885CHRM2 4416/4885 |
| US-20150132258-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HDGF, AZI2 | HSD11B1 89/4885FUCA1 3931/4885CHRM2 4416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.